Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.
about
Immunotoxicity of monoclonal antibodiesPneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis RecommendationsEchinocandin treatment of pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infectionSusceptibility of Pneumocystis to echinocandins in suspension and biofilm culturesInvasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitorsAre members of the fungal genus pneumocystis (a) commensals; (b) opportunists; (c) pathogens; or (d) all of the above?MyD88 signaling regulates both host defense and immunopathogenesis during pneumocystis infectionPulmonary manifestations of inflammatory bowel diseasePulmonary manifestations of Crohn's disease.Comparative genomics of pneumocystis species suggests the absence of genes for myo-inositol synthesis and reliance on inositol transport and metabolism.Anti-TNFα antibody infliximab treatment for an infant with fistulising Crohn's disease.Complications of tumor necrosis factor-α blockade in chronic granulomatous disease-related colitisThe state of research for AIDS-associated opportunistic infections and the importance of sustaining smaller research communities.Analogs of pentamidine as potential anti-Pneumocystis chemotherapeutics.Colonization by Pneumocystis jirovecii and its role in disease.Type 1 interferons suppress accelerated osteoclastogenesis and prevent loss of bone mass during systemic inflammatory responses to Pneumocystis lung infection.Glycosphingolipids mediate pneumocystis cell wall β-glucan activation of the IL-23/IL-17 axis in human dendritic cells.Crohn's disease successfully treated with infliximab in a patient receiving hemodialysis: case report and review of the literature.Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis.Cavitary pulmonary disease.Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care.Prevention of infection caused by immunosuppressive drugs in gastroenterology.Infliximab in dermatological treatment: beyond psoriasis.Biofilm formation by Pneumocystis sppParenchymal cell TNF receptors contribute to inflammatory cell recruitment and respiratory failure in Pneumocystis carinii-induced pneumonia.Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.Infliximab for the treatment of plaque psoriasis.Immunizations in patients with inflammatory bowel disease.Update on the diagnosis and treatment of Pneumocystis pneumonia.Pneumocystis jirovecii infection: Cell wall (1→3)-β-D-glucan biology and diagnostic utility.A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease.Pulmonary diseases associated with inflammatory bowel diseases.The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.Safety of biologic therapy in rheumatoid arthritis.Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome.Selective TNF-α inhibitor-induced injection site reactions.What is left when anti-tumour necrosis factor therapy in inflammatory bowel diseases fails?Fungal infections of the gastrointestinal tract in the immunocompromised host: an update.Pneumocystis jirovecii pneumonia in patients receiving tumor-necrosis-factor-inhibitor therapy: implications for chemoprophylaxis.Infection risk associated with anti-TNF-α agents: a review.
P2860
Q24653374-41F6F9D7-66AF-433D-911E-5929230DE917Q26781920-DF0762C1-5B31-49BD-B00D-4C405CC1EE63Q28472713-01B4C3A7-6348-474E-AD89-E6D02C5BD4BAQ28477349-A28256F3-EC53-4550-9ADD-147DEE2EA318Q29302324-DD1C3616-BCC1-40FE-B92C-88D11D4F85D4Q33707383-03B65B10-046B-4456-8C20-33E684765154Q34074728-E63865E2-7F03-462B-8DAF-D2909BFE07E1Q34303009-BEEB7342-1F39-4D32-9F70-C93E4094FF25Q34397357-03FF25E4-71A3-46C1-B7C3-0A8E11D5502CQ34461881-22619806-73B8-415F-9992-4DD2B5425125Q34525280-CF4A4E7A-1267-46D8-A44A-EB7F73B8C7ABQ35019838-99E07EBD-7E1C-43C0-BB4C-D91A18A76850Q35739010-DD9B0394-FCE3-4BAF-B4D8-469FA75084E2Q35740410-D11633BF-33EA-44B9-ABE5-DE14372E7C0CQ35940586-8AD580D9-A6A7-41AE-A86A-9B20D1BB6E3FQ36071793-AB5D7A03-6006-4C86-B30E-9BAE962714DAQ36110545-9566E580-7722-4119-BCD2-ED65E7044F69Q36150895-057A9D70-2323-4DEF-8CB4-048F40E2D63BQ36434896-52E4201D-90BC-447E-809C-0EA135F35420Q36538804-D9D79527-E315-460D-90DB-AAF9FFE0DE52Q36948496-6FD1B630-CF24-45FA-87DF-E9EEB20A7E06Q36971789-8ABA9F4C-77A4-45D9-90AB-4FC4CF9D704FQ37032659-59953BA3-F557-4D3A-9ECA-E4BB5BBDB5FEQ37099386-68B52579-879A-4DE0-92E1-BB966D998A33Q37163093-DB8918AB-9D1E-4F7C-8B6A-D817F190FDC9Q37290665-BDFD1310-4292-4B9B-BC09-5CA466A1A693Q37307554-84735F51-E242-4C27-AD50-C17A8E13B5C5Q37466464-AA6CC1EE-5261-4AD4-B47E-DF7419DAFC2CQ37782191-CEE0FC58-D5EF-4D84-899A-3BF944AB544AQ37790390-72BF057A-89A6-4318-B00C-4B7402D613CBQ37814549-212F4D91-2659-4B9A-BA4A-7395F8420C54Q37814554-068B335E-9991-421B-B064-40377A90CF59Q37918330-710C4413-5617-4958-94F3-15F54EE7FF3EQ37944433-C494DAC9-2CA1-434C-8E5C-7142EFA29786Q38039139-A2CDC5A2-9244-4CCA-9100-8AF61B972C59Q38075021-D512A780-3EF4-4A94-B38B-2DCA1C3E539CQ38191583-096D498A-1221-4F93-A3E8-FD575400B99EQ38218733-FD3BFA68-A39F-420A-86E9-4016202F8717Q38245616-981E132E-8067-4202-98A1-815268849760Q38335718-86B7AFA7-6B43-440F-8342-EF97E3E042E5
P2860
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.
@en
type
label
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.
@en
prefLabel
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.
@en
P1476
Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.
@en
P2093
Nirmal Kaur
Thomas C Mahl
P2888
P304
P356
10.1007/S10620-006-9250-X
P577
2007-04-11T00:00:00Z